Study of the effects of long-term outcomes of autologous peripheral blood stem cell reinfusion in patients with decompensated cirrhosis.
10.3760/cma.j.cn501113-20220228-00091
- Author:
Li Na CUI
1
;
Xiu Fang WANG
1
;
Rui Qing SUN
1
;
Juan DENG
1
;
Zheng Jun GAO
1
;
Xin Min ZHOU
1
;
Chang Cun GUO
1
;
Gui JIA
1
;
Yu Long SHANG
1
;
Chun Mei YANG
1
;
Ying HAN
1
Author Information
1. Xijing Hospital of Digestive Diseases, Air Force Military Medical University, Xi'an 710032, China.
- Publication Type:Observational Study
- MeSH:
End Stage Liver Disease;
Follow-Up Studies;
Humans;
Liver Cirrhosis/drug therapy*;
Middle Aged;
Peripheral Blood Stem Cells;
Severity of Illness Index;
Treatment Outcome
- From:
Chinese Journal of Hepatology
2022;30(3):279-284
- CountryChina
- Language:Chinese
-
Abstract:
Objective: Autologous peripheral blood stem cells (PBSC) derived from bone marrow can promote liver regeneration and improve the liver function of patients, but there are few studies on its effect on the long-term outcomes in patients with decompensated cirrhosis. Based on previous work, this study observed the clinical outcomes of PBSC treatment in patients with decompensated cirrhosis for 10 years, in order to provide more data support for the safety and efficacy of stem cells in clinical applications. Methods: Data of patients with decompensated liver cirrhosis who completed PBSC treatment in the Department of Gastroenterology of the First Affiliated Hospital of Air Force Military Medical University from August 2005 to February 2012 were included. The follow-up endpoint was death or liver transplantation, and patients who did not reach the follow-up endpoint were followed-up for at least 10 years. The patients with decompensated liver cirrhosis who met the conditions for PBSC treatment but did not receive PBSC treatment in our hospital during the same period were used as controls. Results: A total of 287 cases with decompensated liver cirrhosis had completed PBSC treatment, and 90 cases were lost to follow-up within 10 years after surgery. A total of 151 cases with complete survival follow-up data were included in the control group. There were no statistically significant differences in baseline information such as gender, age, etiological composition and liver function score between the two groups. The 10-year survival rate was higher in PBSC than control group (37.56% vs. 26.49%, P<0.05). Cholinesterase, albumin, international normalized ratio, Child-Turcotte-Pugh score, model for end-stage liver disease score, and other indicators were gradually recovered within 3 months to 1 year after PBSC treatment, and stabilized at a more desirable level in the long-term after follow-up for up to 10 years. There was no statistically significant difference in the incidence of liver cancer between the two groups (25.22% vs.31.85%, P=0.267). The age of onset of hepatocellular carcinoma was later in PBSC than control group [(56.66±7.21) years vs. (52.69±8.42) years, P<0.05]. Conclusions: This long-term observational follow-up study of more than ten years confirms that PBSC treatment can bring long-term benefits to patients with decompensated cirrhosis, with good long-term safety, thus providing more data support on the safety and efficacy of stem cells for clinical applications.
